The sodium-glucose cotransporter 2 (SGLT2) inhibitor drugs have emerged as a prospective therapeutic choice for the treatment of cardiovascular disorders [11,12]. Originally developed as SGLT2 inhibitors for the treatment of type 2 diabetes mellitus, these drugs are now being used for cardiovascular disorders as well, owing to their glucose-lowering effects [13-15]. The nephron tubules in the kidneys are the targeted site for these drugs to inhibit glucose reabsorption, increase glucose excretion, and directly lower blood glucose levels [16]. This evidence concerns the gene SLC5A2 and diabetes mellitus.